Sonoma Pharmaceuticals Files 8-K

TL;DR

Sonoma Pharma dropped an 8-K on 8/21, likely about a new deal.

AI Summary

Sonoma Pharmaceuticals, Inc. filed an 8-K on August 21, 2024, reporting a material definitive agreement and financial statements. The filing date indicates events occurred on or around August 19, 2024. The company, formerly Oculus Innovative Sciences, Inc., is based in Boulder, CO.

Why It Matters

This 8-K filing signals a significant event or agreement for Sonoma Pharmaceuticals, Inc., potentially impacting its business operations or financial standing.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for a material definitive agreement and financial statements, not indicating immediate financial distress or significant negative events.

Key Players & Entities

• Sonoma Pharmaceuticals, Inc. (company) — Registrant
• August 19, 2024 (date) — Earliest event reported
• August 21, 2024 (date) — Filing date
• Oculus Innovative Sciences, Inc. (company) — Former company name
• Boulder, CO (location) — Principal executive offices

FAQ

Filing Documents

• sonoma_8k.htm (8-K) — 30KB
• sonoma_ex1001.htm (EX-10.1) — 64KB
• 0001683168-24-005938.txt ( ) — 278KB
• snoa-20240819.xsd (EX-101.SCH) — 3KB
• snoa-20240819_lab.xml (EX-101.LAB) — 33KB
• snoa-20240819_pre.xml (EX-101.PRE) — 22KB
• sonoma_8k_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. Effective August 19, 2024, we entered into a distribution agreement with Medline Industries, LP, for the marketing and distribution of our wound care products. The agreement is for an initial term of five years, subject to automatic one-year renewal periods. The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a redacted copy of which is filed herewith as Exhibit 10.1. This report contains forward-looking strategies, predictions or any other statements related to our future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our Annual Report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1* Distribution Agreement, dated August 19, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). ___________________ Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request. * Some exhibits or schedules to the agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedule or exhibit to the SEC upon request. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: August 21, 2024 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR